Literature DB >> 3083890

Quantitation and properties of the active and latent plasminogen activator inhibitors in cultures of human endothelial cells.

E G Levin.   

Abstract

Human endothelial cells release two forms of a plasminogen activator-specific inhibitor: an active form that readily binds to and inhibits plasminogen activators and an inactive or latent form that has no anti-activator activity but which can be activated by denaturation. Latent and active forms of plasminogen activator-specific inhibitor were measured in cultures of human umbilical vein endothelial cells. Latent inhibitor was activated by treatment with 1% sodium dodecyl sulfate (SDS), and both forms were assayed by the 125I-fibrin plate method. After 16 hours, the conditioned medium contained 104.6 U/mL latent inhibitor activity and 2.6 U/mL active inhibitor. The level of each form in the culture medium increased with time although the activity associated with the latent form rose more rapidly: the ratio of latent to active inhibitor activity was 12 at four hours (10.3 U/mL v 0.86 U/mL) and reached 56 at 24 hours (155.3 U/mL v 2.80 U/mL). Intracellular inhibitor activity was associated with the active form only; no additional inhibitor activity was observed following SDS treatment of cell extracts. A decline in active inhibitor activity occurred during incubation at 37 degrees C with a 50% reduction in activity occurring in two hours. Treatment of conditioned medium with 10 U/mL thrombin also resulted in a loss of active inhibitor activity. The latent inhibitor, however, was not affected by either of these conditions. The inhibitor activity lost during incubation at 37 degrees C or thrombin treatment could be regenerated by SDS treatment, suggesting that the loss of the active inhibitor activity represented a conversion of this form to its latent counterpart. Thus, the concentration, stability, and regulation of these two forms of plasminogen activator inhibitor in human endothelial cell cultures differ significantly.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3083890

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  Transforming growth factor-ßs as modulators of pericellular proteolytic events.

Authors:  J Keski-Oja; J Lohi; M Laiho
Journal:  Cytotechnology       Date:  1989-12       Impact factor: 2.058

2.  Secretion of plasminogen activator inhibitor by normal rat pleural leukocytes in culture.

Authors:  X Y Li; G M Brown; D Lamb; K Donaldson
Journal:  Lung       Date:  1990       Impact factor: 2.584

3.  Butyrate stimulates tissue-type plasminogen-activator synthesis in cultured human endothelial cells.

Authors:  T Kooistra; J van den Berg; A Töns; G Platenburg; D C Rijken; E van den Berg
Journal:  Biochem J       Date:  1987-11-01       Impact factor: 3.857

4.  The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator.

Authors:  T L Lindahl; P I Ohlsson; B Wiman
Journal:  Biochem J       Date:  1990-01-01       Impact factor: 3.857

5.  Plasminogen activator inhibitor-type I is a major biosynthetic product of retinal microvascular endothelial cells and pericytes in culture.

Authors:  A E Canfield; A M Schor; D J Loskutoff; S L Schor; M E Grant
Journal:  Biochem J       Date:  1989-04-15       Impact factor: 3.857

Review 6.  The haemostatic function of the vascular endothelial cell.

Authors:  H A Bull; S J Machin
Journal:  Blut       Date:  1987-08

7.  Expression of plasminogen activator inhibitor type 2 in normal and psoriatic epidermis.

Authors:  B Lyons-Giordano; D Loskutoff; C S Chen; G Lazarus; M Keeton; P J Jensen
Journal:  Histochemistry       Date:  1994-02

8.  The expression and localization of urokinase-type plasminogen activator and its type 1 inhibitor are regulated by retinoic acid and fibroblast growth factor in human teratocarcinoma cells.

Authors:  J Tienari; T Alanko; E Lehtonen; O Saksela
Journal:  Cell Regul       Date:  1991-04

9.  Kinetics of the inhibition of plasminogen activators by the plasminogen-activator inhibitor. Evidence for 'second-site' interactions.

Authors:  J Chmielewska; M Rånby; B Wiman
Journal:  Biochem J       Date:  1988-04-15       Impact factor: 3.857

10.  Tissue-type plasminogen activator of colonic mucosa in ulcerative colitis. Evidence of endothelium-derived fibrinolytic activation.

Authors:  I Kurose; S Miura; M Suematsu; H Serizawa; D Fukumura; H Asako; T Hibi; M Tsuchiya
Journal:  Dig Dis Sci       Date:  1992-02       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.